Literature DB >> 11117427

Influence of dose and age on the response of the allopurinol test for ornithine carbamoyltransferase deficiency in control infants.

E Riudor1, J A Arranz, M Rodés, V Rubio, M Sentís, A B Burlina.   

Abstract

Measurement of urinary orotidine and orotic acid after an oral allopurinol challenge is an important diagnostic test for ornithine carbamoyltransferase deficiency that is sometimes used in infants (< 1 year of age), although there is little information on normal test results in this age group. We found higher orotidine excretion in normal infants than in older children given the test, whereas orotate excretion was similar in both groups. The increased orotidine excretion appears to be due to the use in the infants of higher allopurinol doses per kilogram of body weight than in the children. The normalized-dose dependency of the orotidine response extends even to adult age. Thus, dose-normalized responses should be used in the test and there is no need for careful age-matching of the controls.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11117427     DOI: 10.1023/a:1005610325170

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  9 in total

1.  Allopurinol-induced orotidinuria. A test for mutations at the ornithine carbamoyltransferase locus in women.

Authors:  E R Hauser; J E Finkelstein; D Valle; S W Brusilow
Journal:  N Engl J Med       Date:  1990-06-07       Impact factor: 91.245

2.  Control of pyrimidine biosynthesis in mammalian tissues. I. Partial purification and characterization of glutamine-utilizing carbamyl phosphate synthetase of mouse spleen and its tissue distribution.

Authors:  M Tatibana; K Ito
Journal:  J Biol Chem       Date:  1969-10-10       Impact factor: 5.157

Review 3.  Pyrimidine nucleotide biosynthesis in animals: genes, enzymes, and regulation of UMP biosynthesis.

Authors:  M E Jones
Journal:  Annu Rev Biochem       Date:  1980       Impact factor: 23.643

4.  Episodic hyperammonemia in adult siblings with hyperornithinemia, hyperammonemia, and homocitrullinuria syndrome.

Authors:  M Tuchman; D S Knopman; V E Shih
Journal:  Arch Neurol       Date:  1990-10

5.  Optimization of allopurinol challenge: sample purification, protein intake control, and the use of orotidine response as a discriminative variable improve performance of the test for diagnosing ornithine carbamoyltransferase deficiency.

Authors:  J A Arranz; E Riudor; M Rodés; M Roig; C Climent; V Rubio; M Sentís; A Burlina
Journal:  Clin Chem       Date:  1999-07       Impact factor: 8.327

6.  Relative frequency of mutations causing ornithine transcarbamylase deficiency in 78 families.

Authors:  M Tuchman; R J Plante; M A Garcia-Perez; V Rubio
Journal:  Hum Genet       Date:  1996-03       Impact factor: 4.132

7.  The allopurinol load test lacks specificity for primary urea cycle defects but may indicate unrecognized mitochondrial disease.

Authors:  J R Bonham; P Guthrie; M Downing; J C Allen; M S Tanner; M Sharrard; C Rittey; J M Land; A Fensom; D O'Neill; J A Duley; L D Fairbanks
Journal:  J Inherit Metab Dis       Date:  1999-04       Impact factor: 4.982

8.  Neonatal onset ornithine transcarbamylase deficiency: A retrospective analysis.

Authors:  N E Maestri; D Clissold; S W Brusilow
Journal:  J Pediatr       Date:  1999-03       Impact factor: 4.406

9.  Allopurinol challenge test in children.

Authors:  A B Burlina; V Ferrari; C Dionisi-Vici; A Bordugo; F Zacchello; M Tuchman
Journal:  J Inherit Metab Dis       Date:  1992       Impact factor: 4.982

  9 in total
  2 in total

1.  Improved quality of life and unchanged magnetic resonance brain imaging after living donor liver transplantation for late-onset ornithine transcarbamylase deficiency: report of a case.

Authors:  Naoki Kawagishi; Kazushige Satoh; Yoshitaka Enomoto; Yorihiro Akamatsu; Satoshi Sekiguchi; Akira Satoh; Keisei Fujimori; Yuhei Takasago; Tetsuya Ito; Toshihiro Ohura; Susumu Satomi
Journal:  Surg Today       Date:  2005       Impact factor: 2.549

2.  Hyperammonemia after capecitabine associated with occult impairment of the urea cycle.

Authors:  Gilbert Chu; Julia Salzman
Journal:  Cancer Med       Date:  2019-04-11       Impact factor: 4.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.